NCT03538522View on ClinicalTrials.gov

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 15, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

October 30, 2019

Conditions
Mild Cognitive ImpairmentAlzheimer DiseaseAlzheimer DementiaDementia, VascularDementia With Lewy BodiesCognitive ImpairmentTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersCognitive Disorder
Interventions
DRUG

N-831(Traneurocin) 10 mg QD

Oral administration of 10 mg capsule of NA-831 QD for 24 weeks

DRUG

NA-831 (Traneurocin) 20 mg QD

Oral administration of 20 mg capsule of NA-831 QD for 24 weeks

DRUG

NA-831 (Traneurocin) 40 mg QD

Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks

DRUG

Placebo oral capsule QD

Oral administration of oral placebo capsule QD or 24 weeks

Trial Locations (2)

1010

NeuroActiva-Clinical Research Unit, Auckland

Unknown

NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland

All Listed Sponsors
lead

Biomed Industries, Inc.

INDUSTRY

NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 | Biotech Hunter | Biotech Hunter